Every material Form 8-K Bionano Genomics, Inc. has filed with the SEC since June 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
In a Regulation FD filing tied to the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, Bionano presented Q2 2026 results showing revenue of $8.2 million, above its $7.5 million to $7.8 million guidance and up 21% from Q2 2025. The company raised the lower end of its FY26 revenue guidance to $31 million to $33 million from $30 million to $33 million, and it projects FY27 revenue of $50 million to $54 million. The filing also repeats that the company's ability to continue as a going concern depends on obtaining significant additional financing.
Q2 2026 revenue was $8.2 million, above guidance of $7.5 million to $7.8 million and up 21% from Q2 2025.
FY26 revenue guidance is $31 million to $33 million, with the lower end raised from $30 million.
FY27 revenue outlook is $50 million to $54 million, with adjusted EBITDA projected at about $0 in the Q4 FY27 exit rate.
The company disclosed that its ability to continue as a going concern requires significant additional financing.
Bionano Genomics reported second quarter 2026 revenue of $8.2 million, up 21% from $6.7 million a year earlier, and a net loss of $7.4 million, up from $6.9 million. The company also gave revenue guidance of $8.2 million to $8.6 million for the third quarter and $31 million to $33 million for full year 2026, and said it fully retired its senior secured convertible debentures during the quarter.
Q2 2026 total revenue was $8.2 million, up 21% from $6.7 million; consumables revenue rose 31% to $4.3 million.
Net loss for the quarter was $7.4 million, compared with $6.9 million in Q2 2025.
Q3 2026 revenue guidance is $8.2 million to $8.6 million; full year 2026 revenue guidance is $31 million to $33 million.
All outstanding senior secured convertible debentures were retired, eliminating secured debt and releasing liens on company assets.
Bionano Genomics said it has hired Alex Hastie, Ph.D., as Chief Scientific Officer, effective July 20, 2026. Dr. Hastie previously worked at the company for 14 years and helped develop its core optical genome mapping technologies, and he will lead the company's global scientific strategy and research initiatives. The filing gives no financial figures, and the appointment is an executive hire rather than a change in financial results.
Alex Hastie, Ph.D., appointed Chief Scientific Officer, effective July 20, 2026
Dr. Hastie previously spent 14 years at Bionano helping develop its core technologies
He will lead global scientific strategy, innovation roadmap and research initiatives
Announced by interim CEO and chairman Albert A. Luderer, Ph.D. in a June 24, 2026 press release
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bionano Genomics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →